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Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-
known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets
VEGF receptors and is considered to be a standard treatment for metastatic or unresectable
clear cell RCC (ccRCC). However, ccRCC eventually develops resistance to sunitinib in
most cases, and the mechanisms underlying this resistance are not fully elucidated. In the
present study, we established unique primary xenograft models, KURC1 (Kyoto University
Renal Cancer 1) and KURC2, from freshly isolated ccRCC specimens. The KURC1 xeno-
graft initially responded to sunitinib treatment, however finally acquired resistance. KURC2
retained sensitivity to sunitinib for over 6 months. Comparing gene expression profiles
between the two xenograft models with different sensitivity to sunitinib, we identified inter-
leukin 13 receptor alpha 2 (IL13RA2) as a candidate molecule associated with the acquired
sunitinib-resistance in ccRCC. And patients with high IL13RA2 expression in immunohis-
tochemistry in primary ccRCC tumor tends to have sunitinib-resistant metastatic site. Next,
we showed that sunitinib-sensitive 786-O cells acquired resistance in vivo when IL13RA2
was overexpressed. Conversely, shRNA-mediated knockdown of IL13RA2 successfully
overcame the sunitinib-resistance in Caki-1 cells. Histopathological analyses revealed that
IL13RA2 repressed sunitinib-induced apoptosis without increasing tumor vasculature in
vivo. To our knowledge, this is a novel mechanism of developing resistance to sunitinib in a
certain population of ccRCC, and these results indicate that IL13RA2 could be one of poten-
tial target to overcome sunitinib resistance.
Introduction
Renal cell carcinoma (RCC) accounts for 2–3% of all malignancies in adults and causes approx-
imately 102,000 deaths worldwide each year [1]. Approximately 30% of newly diagnosed
patients present with locally advanced and/or metastatic RCC [2, 3]. Treatment of metastatic
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RCC is difficult because it shows limited or no responsiveness to conventional anticancer ther-
apies such as radiation, chemotherapy, and cytokine therapy [4].
Recent increased understanding of the underlying molecular biology of RCC has established
the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR)
pathways as relevant therapeutic targets [5]. Agents targeting the VEGF receptor and mTOR
complex 1 (mTORC1) are more effective than traditional cytokine therapy and improve the
prognosis of RCC patients [6].
Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), includ-
ing VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor
receptors (PDGFR-α and PDGFR-β), fms-related tyrosine kinase 3 (FLT3), stem cell growth
factor receptor KIT, and RET [7, 8], and is currently considered as a standard first-line treat-
ment for metastatic clear cell RCC (ccRCC) [9, 10]. Sunitinib as first-line treatment of patients
with metastatic RCC resulted in longer overall survival and progression-free survival compared
with patients treated with conventional drugs [9–11]. However, despite the efficacy of suniti-
nib, ccRCC often develops resistance to sunitinib, and the majority of patients who receive
sunitinib for treatment of advanced ccRCC exhibit progressive disease after 1 year of treatment
[5]. Several hypotheses have been proposed regarding the mechanism underlying resistance to
sunitinib [12, 13], but they have not yet been fully elucidated.
Previous reports indicated that primary xenograft models directly transplanted from patient
surgical specimens can recapitulate the original clinical course because these implanted tumor
grafts contain both epithelial and stromal cells that may co-proliferate to form histologically
complex tumors in host mice [14, 15]. Therefore, in this study, we aimed to clarify the mecha-
nisms underlying resistance to sunitinib by establishing such primary xenograft models from
patient-derived tumor tissues and to identify potential targets to overcome sunitinib resistance.
Materials and Methods
Patients and RCC samples
RCC tumor specimens were obtained at the Department of Urology, Kyoto University Hospital
with appropriate written informed consent. This study was approved by the Kyoto University’s
institutional review board (IRB approved number G52: Research about an individualized treat-
ment for urological cancer using gene profiling).
Cell culture
786-O and Caki-1 cell lines were purchased from the American Type Culture Collection
(Rockville, MD). Cells were cultured routinely in Dulbecco's Modified Eagle Medium (Invitro-
gen, Carlsbad, CA) containing 10% fetal bovine serum supplemented with 1% penicillin/strep-
tomycin. Caki-1 cells stably infected with shRNA lentivirus and 786-O cells stably infected
with pBABE-puro retroviruses were selected in the presence of 1.5 μg/ml puromycin.
Generation of xenograft models
All experiments involving laboratory animals were performed in accordance with the Guide-
lines for Animal Experiments of Kyoto University (Permit Number 13336: Research of the
novel mechanisms developing resistance to anti-angiogenic treatment in renal cell carcinoma).
To establish primary xenograft models, local tumors of the kidney were resected by radical
nephrectomy, minced into 20–30 mm3 fragments, and subcutaneously transplanted into
5-week-old CB-17/Icr-crj SCID mice (Charles River, Yokohama, Japan) on the day of surgery.
KURC1 (Kyoto University Renal Cancer 1) and KURC2 xenografts were established within
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3–4 months after the first inoculation. Xenograft tumors were extracted and transplanted into
several SCID mice.
To establish cell line xenograft models, a total of 1.0×107 cells were subcutaneously injected
into both flanks of 5–6-week-old female BALB/cA Jcl nude(nu/nu) mice (CLEA, Tokyo, Japan)
and tumor volumes were measured twice a week. All experiments were performed under
sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. Following
the experimental procedures, all animals were euthanized by carbon dioxide and tumors were
excised.
In vivo sunitinib administration
Sunitinib provided by Pfizer Global Pharmaceuticals was diluted in dimethyl sulfoxide
(DMSO). Sunitinib treatment for primary or cell line xenograft tumors was commenced from
the fourth week after transplantation. Forty mg/kg sunitinib was orally administered once a
day for the treatment group, and vehicle only was given to the control group. Affected tumors
were considered resistant when the tumor growth rate was comparable to that of the control
tumor. Tumors were resected 24 hours later from the last sunitinib or vehicle administration.
Because of the difference of growth rate and sunitinib response between 786-O and Caki-1
xenograft tumors[16, 17], we needed to observe for a longer time in Caki-1 xenograft experi-
ment than in 786-O, consequently sacrificed at different time points with each cell lines.
Antibodies and reagents
Antibodies were purchased commercially as follows: human IL13RA2 (MAB614 for immuno-
blotting and AF146 for immunohistochemistry, R&D Systems, Minneapolis, MN), human
STAT6, human phospho-STAT6 Y641 (Cell Signaling Technology, Beverly, MA), human
ssDNA (IBL, Tokyo, Japan), human β-actin, human N-cadherin and mouse CD31 (Abcam,
Cambridge, MA).
Immunohistochemistry
Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded 17 clini-
cal ccRCC samples or xenograft tissues as described previously [18]. The degree of IL13RA2
immunopositivity in clinical samples was assessed as none, weak, or strong, and the assessment
was performed with no prior knowledge of the response to sunitinib. Tumor microvessel den-
sity (MVD) was evaluated using CD31 as an endothelial marker. MVD was determined in 3
fields of each sample according to the method of Weidner [19]. Apoptosis was evaluated by
counting the ssDNA-positive nuclei rate. Numbers of total or ssDNA-positive apoptotic nuclei
were automatically quantitated in 3 fields of each sample using ImageJ software (National
Institutes of Health, Bethesda, MD). The ssDNA-positive rate was calculated as the percentage
of positive tumor nuclei divided by the total number of tumor nuclei examined.
Protein extraction and immunoblot analysis
Whole cell proteins were isolated from snap-frozen specimens or cultured cells and analyzed
by immunoblotting as previously described [20, 21].
Quantitative real-time PCR (qPCR)
Total RNA was extracted from vehicle-treated control, sunitinib-treated sensitive or resistant
tumors of KURC1, KURC2, and cell line subclones, as previously described [22]. cDNA was
synthesized from total RNA using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). qPCR
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was performed using SYBR green PCRMaster Mix (Applied Biosystems, Foster City, CA) and
monitored using GeneAmp 5700 (Applied Biosystems). PCR reactions were performed in trip-
licate. The thermal cycling conditions were 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. The
values were normalized to the levels of amplified glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The primer sequences were as follows: GAPDH, 50-GAAGGTGAAGGTCGGAG
TC-30 (sense) and 50-GAAGATGGTGATGGGATTTC-30 (antisense); and IL13RA2, 50-TTGC
TTGGCTATCGGATGCT-30 (sense) and 50-GGGTTAACTTTTATCTCGGTGTCTGA-30
(antisense).
Microarray analysis
For microarray experiments, we used total RNA extracted from two resistant, one sensitive,
and two control KURC1 tumors, and one sensitive and one control KURC2 tumor. Microarray
analyses were performed at Genetic Lab Co., Ltd. (Sapporo, Japan) using GeneChip Human
Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA). The results were analyzed using GeneSpring
GX (Agilent, Santa Clara, CA) by Genetic Lab Co., Ltd. Our microarray data was registered at
the NCBI GEO (GSE66346).
Lentiviruses
Lentivirus-based plasmids containing pLKO.1 shRNA sets to human IL13RA2
(RHS4533-NM000640; TRCN0000058523-27) were purchased from Open Biosystems (Hunts-
ville, AL). Non-silencing shRNAs (Open Biosystems) were used as negative controls. The
experimental procedure for shRNA transfection was performed according to the Open Biosys-
tems technical manual.
Plasmid construction and retroviral expression
Full-length IL13RA2 cDNA was amplified by PCR from Caki-1 cell cDNA using PrimeSTAR
HS DNA polymerase (Takara Bio, Shiga, Japan) and cloned into the pBABE-puro retroviral
vector. The oligonucleotide sequences used in the construction of the expression construct
were as follows: IL13RA2, 50-CACCATGTATCCATATGATGTTCCAGATTATGCTGGATC
CGCTTTCGTTTGCTTGGCTATCGGATGCTTATATAC-30 and 50-ACACCCTAACTGAC
ACACATTCCCAGGGTCGACTCATGTATCACAGAAAAATTCTGGAATCATTTTTG-30.
The PCR products were inserted into pBABE-puro vector at BamH1/Xho1 sites using an Infu-
sion-HD Cloning Kit (Takara Bio, Shiga, Japan). G3T-hi packaging cells were infected with ret-
roviral plasmids using a Retrovirus Packaging Kit (Ampho, Takara Bio). These experiments
were performed according to the manufacturer’s instructions.
Oncomine database analysis
Oncomine data was obtained from Vasselli et al. [23] and Bittner. Expression levels of
IL13RA2 were compared with tumor grade and prognosis in ccRCC.
Statistical analysis
Data are expressed as the mean ± SE. The significance of differences between means was
assessed using the Student’s t-test. In vitro cell proliferation and tumor growth in vivo were
analyzed by two-way repeated ANOVA. P values of< 0.05 were considered statistically
significant.
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Results
Establishment of the primary RCC xenograft model and acquisition of
resistance to sunitinib
Two cohorts of primary xenografts were established and stably engrafted following three or
more passages in vivo. We named them as primary xenograft KURC1 and KURC2. Histopath-
ological diagnosis of primary tumor was clear cell type RCC of Grade 2> 3, pT2N0M0 for
KURC1 and clear cell type RCC, G3, pT3aN0M1 for KURC2. Each xenograft mostly recap-
tured the histopathological features of original tumors in tumor grade and architecture (Fig 1A).
We have found necrosis in the center of tumors and N-cadherin was strongly expressed in both
xenograft tumors (S1 Fig).
Upon treatment with sunitinib, tumor progression was observed in KURC1 after 4 weeks of
treatment. Conversely, KURC2 retained sensitivity for more than 6 months (Fig 1B). Impor-
tantly, when KURC1 tumors that acquired sunitinib resistance were transferred to other SCID
mice and treated with sunitinib again, the resistant phenotype was successfully reproduced.
After this procedure was repeated five times, latency period of KURC1 sunitinib group (named
as sunitinib 5th) was shorter than vehicle group (vehicle 5th), and the xenograft of sunitinib 5th
acquired a complete resistance to sunitinib with maintaining clear-cell histological appearance
and exhibited a similar tumor growth curve to the xenograft treated with vehicle 5th (Fig 1C).
Interleukin-13 receptor, alpha 2 (IL13RA2) as a candidate molecule
responsible for the acquired resistance to sunitinib
To clarify the mechanism of sunitinib resistance, we compared the gene expression profile of
representative xenografts with sensitive and resistant status (GSE66346). KURC1 and KURC2
sensitive tumors treated with sunitinib were harvested at day 30 and 60, respectively (Fig 1B).
Sunitinib-treated resistant KURC1 tumors were taken at day 50. Additionally, corresponding
tumors treated with vehicle were harvested as a control and the ratio of expression levels of
each gene under sensitive and resistant status to that of control was calculated (Fig 1B).
Three genes, IL13RA2, MTMR7 and FAM5B, were significantly highly expressed in suniti-
nib-resistant KURC1 xenografts (day 50) compared with those treated with vehicle
(ratio = 6.50, 3.37, 2.95, respectively). Conversely, the expression levels of these genes were not
significantly changed in sunitinib-sensitive KURC1 (day 30) and sunitinib-sensitive KURC2
compared with those in vehicle-treated KURC1 and KURC2 (Table 1).
Among the three genes, qPCR analysis confirmed that IL13RA2 mRNA was significantly
upregulated in sunitinib-resistant KURC1 compared with sunitinib-sensitive KURC1 or those
treated with vehicles (Fig 2A and 2B). The other candidate genes, FAM5B and MTMR7, were
also up-regulated in our experimental model of KURC1 and KURC2. But the expression was
very low level, therefore we didn’t pick up these genes (S2 Fig).
Immunohistochemical analysis confirmed that the protein expression of IL13RA2 was upre-
gulated in sunitinib-resistant KURC1 tumors compared with sunitinib-sensitive KURC1
tumors or those treated with vehicle (Fig 2B). KURC1 with complete resistance (mentioned
above) showed extremely high IL13RA expression levels compared with those treated with
vehicle alone (S3A and S3B Fig). The same analyses using KURC2 tumors showed no signifi-
cant changes in IL13RA2 levels between sunitinib-treated and vehicle-treated tumors (Table 1,
Fig 2A & S3C Fig).
Next, we examined IL13RA2 expression in human metastatic ccRCC tumors. Tumor sam-
ples were collected from primary lesion of metastatic ccRCC patients. These patients were sub-
sequently treated with sunitinib and the response was evaluated by Response Evaluation
IL13RA2 and Resistance to Sunitinib in ccRCC
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Criteria in Solid Tumors guidelines. Five patients showed progressive disease within 3 month
under sunitinib treatment (non-responder), whereas 12 patients showed partial response or
stable disease over 3 month (responder). Although 3 patients were responder to sunitinib even
high expression of IL13RA2 in their primary tumors, most patients with primary ccRCC
tumors of higher IL13RA2 expression were non-responder group when they were treated with
sunitinib for metastatic sites compared with those of lower IL13RA2 expression (Fig 2C). Col-
lectively, these data suggested that IL13RA2 expression levels might be correlated to the sensi-
tivity to sunitinib in ccRCC.
Higher expression of IL13RA2 causes sunitinib resistance and tumor
progression in ccRCC
To clarify the effect of IL13RA2 on sunitinib sensitivity, sunitinib-sensitive 786-O cells [24]
were infected with retrovirus encoding IL13RA2 or empty vector. The expression of exogenous
IL13RA2 was confirmed by western blot (Fig 3A). Both cell lines were inoculated into nude
mice to examine the sensitivity to sunitinib. IL13RA2 expression was still up-regulated in the
xenograft tumors of IL13RA2-expressing 786-O (S4A Fig). Notably, the tumor growth of xeno-
grafts from IL13RA2-expressing 786-O cells was not suppressed by treatment with sunitinib
(Fig 3C), while that of mock-transfected 786-O xenografts was significantly inhibited by suniti-
nib (Fig 3B). Moreover, tumor growth of IL13RA2-expressing 786-O xenografts was signifi-
cantly more rapid than that of mock-transfected 786-O xenografts (S4B Fig).
To further confirm the effects of IL13RA2 on ccRCC, sunitinib-resistant Caki-1 cells [17]
were infected with a lentivirus encoding scrambled or IL13RA2 shRNA. ShRNA-mediated
knockdown of IL13RA2 successfully reduced the expression of IL13RA2 protein levels (Fig
3D). IL13RA2 expression was also maintained in the xenograft tumors (S5A Fig). Importantly,
Caki-1 xenografts with IL13RA2 shRNA exhibited significantly higher sensitivity to sunitinib
than those with scrambled shRNA (Fig 3E and 3F). Additionally, tumor growth in vivo was sig-
nificantly suppressed by shRNA-mediated knockdown of IL13RA2 (S5B Fig).
Taken together, these results further supported the notion that IL13RA2 expression is asso-
ciated with sensitivity to sunitinib and the biological aggressiveness of ccRCC.
Fig 1. KURC1 tumors develop resistance to sunitinib but KURC2 remained sensitive. (A) Hematoxylin and eosin (H&E) staining of an original RCC
surgical specimen and xenograft KURC1 and KURC2 tumor tissue. Scale bar, 50 μm. (B) The sequential changes of KURC1 and KURC2 xenograft tumors
treated with sunitinib or vehicle only and (C) Left: KURC1 tumor volume at 4 weeks later from passage (sunitinib treatment day 0). Right: The sequential
changes of KURC1 sunitinib 5th and vehicle 5th. KURC1 repeatedly treated with sunitinib or vehicle 5th. Each time point represents the mean ± SE of tumor
volume in each group. Day 0 is the first day of sunitinib administration at 4 weeks after transplantation. The difference in tumor size between sunitinib 5th
group and vehicle 5th group in KURC1 was not statistically significant using two-way repeated ANOVA. Arrowed bars indicate the periods of sunitinib
administration. ▼ indicates the time point when tumors were resected.
doi:10.1371/journal.pone.0130980.g001
Table 1. mRNA changes after sunitinib treatment in KURC1 and KURC2 xenograft tumors.
refseq genedescription genesymbol KURC1R/C KURC1S/C KURC2S/C
NM_000640 interleukin 13 receptor, alpha 2 IL13RA2 6.50 0.99 1.45
NM_004686 myotubularin related protein 7 MTMR7 3.37 1.21 1.13
NM_021165 family with sequence similarity 5, member B FAM5B 2.95 1.10 0.88
Microarray analysis was performed using Affymetrix GeneChip Human Gene 1.0 ST Arrays. These 3 genes were up-regulated more than 2.5-fold
expression in sunitinib-resistant KURC1 tumor xenograft compared with control.
doi:10.1371/journal.pone.0130980.t001
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IL13RA2-mediated resistance to sunitinib is caused by the inhibition of
sunitinib-induced apoptosis without increasing tumor microvasculature
Next, we sought to explore the mechanisms of IL13RA2-mediated resistance to sunitinib.
Xenograft tumors derived from 786-O and Caki-1 subclone were resected after 21days, 75days
of sunitinib treatment, respectively. Since increased MVD was associated with sunitinib resis-
tance [24, 25], we first measured MVD in a series of xenograft tumors from 786-O- or Caki-
1-derived cells. As expected, MVD was significantly decreased in sunitinib-sensitive 786-O
mock xenografts after the treatment (Fig 4A & S6A Fig). To our surprise, sunitinib significantly
suppressed tumor microvasculature in specimens from resistant 786-O IL13RA2 cells (Fig 4A
& S6A Fig). Similarly, CD31 immunostaining exhibited significantly decreased MVD in both
sunitinib-treated sh-scrambled and shIL13RA2 Caki-1-derived xenografts irrespective of their
sensitivity to the drug (Fig 4B & S6B Fig). These results indicated that IL13RA2 did not grossly
affect the effect of sunitinib on tumor microvasculature and might play significant roles in the
survival of tumor cells under the stressed circumstances of diminished MVD.
A previous study reported that higher expression of IL13RA2 was associated with tumor
progression of certain types of cancer [26, 27]. Furthermore, IL13RA2 was shown to inhibit
apoptotic cell death through the suppression of STAT6 phosphorylation by functioning as a
decoy receptor for IL13 signaling. In fact, siRNA-mediated knockdown of IL13RA2 induced
apoptosis in glioblastoma cells [28]. We next examined if IL13RA2 could suppress STAT6
phosphorylation in ccRCC cells. As shown in Fig 4C, the abundance of pSTAT6 was reduced
in 786-O IL13RA2 cells compared with mock infected cells. This was also true in Caki-1 cells,
in that shRNA-mediated knockdown of IL13RA2 resulted in the upregulation of phosphory-
lated STAT6 (Fig 4D).
Based on these results, we examined the effects of IL13RA2 on apoptotic cell death induced
by sunitinib treatment in vivo by analyzing ssDNA positive rate in xenograft tumors with
IL13RA2 overexpression. The positive ratio of ssDNA immunostaining was 15% when xeno-
grafts from mock-transfected 786-O cells were treated with sunitinib, and 1.5% in xenografts
treated with vehicle. However, the positive ratio of ssDNA staining was only 4.3% when xeno-
grafts from IL13RA2-transfected 786-O cells were treated with sunitinib compared with 0.8%
when treated with vehicle. Thus, xenografts from IL13RA2-expressing 786-O cells were more
likely to escape from apoptosis by sunitinib treatment than mock-transfected 786-O cells (Fig
4E & S7A Fig).
As for xenograft tumors derived from Caki-1 cells, the number of apoptotic tumor cells
indicated by ssDNA immunopositivity was not significantly increased by sunitinib treatment
compared with vehicle in scramble shRNA-infected cells. However, in those derived from
Caki-1 shIL13RA2 cells, apoptosis was significantly induced by sunitinib treatment compared
with vehicle only (Fig 4F & S7B Fig).
Finally, we examined if the inhibition of apoptosis regulated the sensitivity and development
of sunitinib resistance in our primary xenograft model KURC1. We first examined the number
of ssDNA-positive cells in both xenografts. Sunitinib treatment significantly increased the
Fig 2. Evaluation of IL13RA2mRNA and protein expression. (A) Evaluation of IL13RA2mRNA expression in KURC1 and KURC2 xenograft tumors
treated with sunitinib or vehicle by qPCR. All samples were prepared in triplicate and data are presented as the mean ± SE from indicated number of
samples. Columns, mean; bar, SE. The difference in the mRNA expression levels between the sunitinib-treated group and control or sensitive group in
KURC1 was statistically significant (*P < 0.01; Students’ t-test). There was no significant difference in KURC2 groups. (B) Immunohistochemical staining of
IL13RA2 in KURC1 xenograft tumors. Scale bar, 50 μm. (C) IL13RA2 expression in human ccRCC tumors with the response to sunitinib treatment evaluated
by immunohistochemistry. ccRCC tumor samples were collected from patients prior to sunitinib treatment. Left: representative pictures of
immunohistochemistry sections of tumors showing none, weak, or strong staining for IL13RA2. Right: ratio of IL13RA2 expression pattern and correlation of
the response to sunitinib treatment. Scale bar, 100 μm.
doi:10.1371/journal.pone.0130980.g002
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number of ssDNA-positive apoptotic cells in sunitinib-sensitive in KURC1 tumors at day 30.
In contrast, in KURC1 sunitinib-resistant tumors at day 50, the number of apoptotic cells
decreased to a level almost comparable to that of vehicle-treated cells at day 50 (Fig 5A). We
next measured MVD in each xenograft. MVD was reduced after the treatment of sunitinib at
day 30 or 50 in KURC1 xenograft tumors, irrespective of sunitinib sensitivity (Fig 5B). In order
to estimate the total number of tumor vessels, MDVmultiply the corresponding tumor vol-
ume. According to calculations, the ratio of number of vessels in control tumor at day 50, sensi-
tive tumor at day 30, and resistant tumor at day 50 were 17, 1, and 3, respectively. Indeed, the
ratio of them in p5 control tumor at day 50 and p5 resistant tumor at day 50 were estimated 2
and 1. These observations implicated total number of tumor vessels was slightly increased
when tumors acquired sunitinib resistance despite of the reduction of MVD, although angio-
genesis was still inhibited by sunitinib even in complete resistance state in our primary xeno-
graft model. Collectively, these data suggested that IL13RA2-mediated resistance to sunitinib
in ccRCC might be primarily caused by the inhibition of apoptosis.
Discussion
Most patients with metastatic or unresectable RCC are treated with angiogenesis inhibitors tar-
geting VEGFR or inhibitors of mTORC1 [29]. In particular, sunitinib is considered to be the
standard treatment option for RCC [30, 31]. Unfortunately, most metastatic RCCs eventually
develop resistance to sunitinib [12]. Although some limited reports have addressed the molecu-
lar mechanisms of the development of resistance to sunitinib or other anti-angiogenic drugs,
these mechanisms are not fully understood.
Several studies suggested that at least four molecular mechanisms mediate acquired resis-
tance to VEGF-targeted anti-angiogenic treatment including sunitinib: 1) activation and/or
upregulation of other pro-angiogenic signaling pathways, for example fibroblast growth factor
1 and 2 (FGF1/2), ephrin A1 and A2 (Efna1/2), and angiopoietin 1 (Ang1) [25]; 2) increased
pericyte coverage of tumor blood vessels; 3) recruitment and survival of myeloid-derived sup-
pressor cells with sustained immune suppression and angiogenesis[32, 33]; and 4) increased
tumor cell invasiveness to escape from oxygen and nutrition deprivation[13, 25, 34]. Another
study suggested that mechanisms of multidrug-resistance to chemotherapy in RCC might also
be involved in decreased intake of tyrosine kinase inhibitors (TKIs), including those related
with membrane structures, ATP-binding cassette (ABC) drug transporters with P-glycoprotein
(P-gp, ABCB1), multidrug resistance associated protein (MRP) 1 (ABCC1), and ABCG2
(breast cancer resistance protein, MXR) [35]. Moreover, Gotink et al. introduced the idea of
lysosomal sequestration as a specific cellular adaptation to toxic TKI concentrations in a TKI-
resistant RCC in vitromodel [36].
Fig 3. Overexpression of IL13RA2 leads to acquired resistance to sunitinib and shRNA-mediated IL13RA2 knockdown induces sensitivity to
sunitinib. (A) Immunoblot analysis of 786-O subclones infected with retrovirus encoding mock or WT IL13RA2. Whole cell extracts were immunoblotted
using the indicated antibodies. Sequential changes in subcutaneous xenograft tumors from 786-O subclones infected with (B) mock or (C) WT IL13RA2
treated with sunitinib and vehicle (control). Each time point represents the mean ± SE of tumor volume in each group. The difference in tumor size between
the treatment group and control was statistically significant in 786-O-mock cells but not statistically significant in 786-O-IL13RA2 cells (*P < 0.05, n.s.: not
significant; two-way repeated ANOVA). The horizontal arrow bars indicate the periods of sunitinib administration. (D) Immunoblot analysis of Caki-1
subclones infected with lentivirus encoding scrambled or IL13RA2 shRNA. Whole cell extracts were immunoblotted using the indicated antibodies.
Sequential changes of subcutaneous xenograft tumors from a Caki-1 subclone infected with (E) scrambled or (F) IL13RA2 shRNA treated with sunitinib and
vehicle (control). Each time point represents the mean ± SE of tumor volume in each group. Day 0 is the first day of sunitinib administration 4 weeks after
transplantation. The difference in tumor size between the treatment group and control was not significant in Caki-1-sh-scrambled cells but statistically
significant in Caki-1-sh-IL13RA2 cells (n.s.: not significant, *P < 0.05; two-way repeated ANOVA). The arrow bars indicate the period of sunitinib
administration.
doi:10.1371/journal.pone.0130980.g003
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However, these proposed mechanisms do not fully address the process of acquired resis-
tance to sunitinib in human RCC, because these mechanisms have not been validated in mod-
els that are well recapitulated for the clinical course of human RCCs. Furthermore, it is also
difficult to compare human clinical tumor tissues before treatment with those after treatment.
Although human cancer cell lines are extremely useful for cancer research [37, 38], many
have been passaged in culture for numerous years, resulting in alterations in their characteris-
tics following adaptations to growth in culture and subsequent expansion [39, 40]. Thus, xeno-
graft tumors derived from these cell lines often look quite different histologically from those
routinely encountered in a clinical pathological laboratory. Therefore, in this study, we estab-
lished two cohorts of primary xenograft models derived from patient surgical tissues that path-
ologically resembled the original tumors. Primary xenograft tumors derived from surgical
specimens retain the histology as well as the gene expression levels, DNA copy number alter-
ations and over 90% of the protein-coding gene mutations of the corresponding tumors [15].
These primary xenograft models are therefore considered to be reasonable models in which to
recapitulate the clinical course of ccRCC treated with sunitinib.
In our primary xenograft models, KURC1 and KURC2 tumors displayed different charac-
teristics regarding sunitinib sensitivity. KURC1 developed resistance to sunitinib after 4 weeks
of treatment but KURC2 remained sensitive for more than 6 months. Although there have
been some reports that primary xenograft tumors acquire resistance to sunitinib, previous
studies showed that re-transplanted tumors in the next cohort of other mice recovered sensitiv-
ity to sunitinib [41]. Surprisingly, in our study, when resistant KURC1 tumors were resected,
re-transplanted into other mice and repeatedly re-administered with sunitinib, KURC1 tumors
finally demonstrated complete resistance to sunitinib after four passages. These different types
of primary xenograft models (resistance-developing KURC1, sensitive KURC2, and completely
resistant KURC1) were useful in our research in identifying novel mechanisms of development
of sunitinib resistance.
To explore the underlying mechanisms of acquired resistance, we performed a microarray
analysis comparing sunitinib-resistant and-sensitive KURC1 with controls, and sunitinib-sen-
sitive KURC2 with controls. Additionally, we performed whole exome sequencing to compare
completely sunitinib-resistant KURC1 with controls. Some gene expression changes were iden-
tified by microarray analysis, but acquired somatic mutations were not found in the exon
regions within these genes of interest (unpublished data). Therefore, we compared gene expres-
sion changes in our data set with those in previous reports and evaluated whether these gene
expression changes were related to sunitinib resistance.
The pro-angiogenic cytokine interleukin 8 (IL-8) was increased in the plasma of sunitinib-
resistant xenograft mice, and neutralization of IL-8 blocked tumor angiogenesis and caused
tumor re-sensitization to sunitinib [24, 42]. Reduction of IFNγ-related angiostatic chemokines
and restoration of CXCL9 delayed acquired resistance to anti-VEGF treatment [43]. MMP1,
SERPNTE1, ANGPTL4, NRP2, ARG2 and INSIG2 were elevated in sorafenib-resistant xeno-
graft tumors derived from a 786-O cell line [44]. However, these gene levels were not upregu-
lated in our primary xenograft model treated with sunitinib (S1 Table). These findings
Fig 4. Evaluation of apoptosis andmicrovessel density after sunitinib treatment in xenograft model derived from cell lines.MVD was decreased by
sunitinib treatment of each xenograft tumor derived from (A) 786-O or (B) Caki-1 subclones regardless of IL13RA2 expression level. MVD was determined
from CD31 staining using Image J software. Statistical analysis was performed using the Students’ t-test (*P < 0.01). Immunoblot analysis of (C) 786-O
subclones and (D) Caki-1 subclones. IL13RA2 expression was negatively correlated with the phosphorylation of STAT6. Whole cell extracts were
immunoblotted using the indicated antibodies. ssDNA staining of xenograft tumors derived from (E) 786-O subclones and (B) Caki-1 subclones treated with
sunitinib or vehicle only. Apoptosis was assessed by calculating the ssDNA positivity rate. Statistical analysis was performed using the Students’ t-test
(*P < 0.05, **P < 0.01).
doi:10.1371/journal.pone.0130980.g004
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suggested that another mechanism is involved in acquired resistance to sunitinib in our pri-
mary xenograft KURC1 model.
IL13RA2 was identified as a candidate molecule associated with sunitinib resistance in our
model KURC1, and IL13RA2 expression was significantly higher in human primary ccRCC
tumor of patients with sunitinib-resistant metastatic sites. Even though 3 patients were
responder to sunitinib whose primary RCC tumors were higher expression of IL13RA2, this
molecule may be one candidate of sunitinib-resistance and other mechanism or molecules
have been reported. Albeit, it would be better that we evaluated IL13RA2 expression level in
the affected tumors after sunitinib treatment or after developing sunitinib-resistance, it is ethi-
cally difficult to obtain such samples. Therefore we evaluated that IL13RA2 expression in
human primary tumors and their systemic response to sunitinib.
Besides, gene expression data derived from Oncomine reported by Vasselli indicated that
ccRCC specimens of Furhman Grade 4 showed a significantly higher expression of IL13RA2
compared with those of Grade 3. Moreover, higher expression of this gene was also signifi-
cantly associated with poor prognosis (dead at 1 year). In general, patients with high grade
ccRCC tumors or patients of poor prognosis developed resistance to sunitinib earlier. These
data might support our results. However other available dataset in ccRCC reported by Bittner
showed IL13RA2 expression was not correlated with tumor grade, albeit it was slightly elevated
in the cases of tumor Grade 4 (S8 Fig). Considering the number of Grade 4 cases was small in
this data set, expression profile with more samples would be necessary to elucidate high
IL13RA2 expression associate with worse clinical features.
IL13RA2 was originally cloned from the human renal cell carcinoma Caki-1 cell line [45].
This protein binds IL13 with high affinity but lacks a cytoplasmic domain and does not appear
to function as a signal mediator, which is slightly dissimilar to interleukin 13 receptor, alpha 1
(IL13RA1) [46]. IL-13 and IL-4 modify the function of macrophages, and IL13RA2 mediates
IL13/4 mediated tumor associated macrophage M1/M2-Th1/Th2 phenotype, especially, IL-13
signaling promote to change M1 to M2[47]. Tumor associated macrophage M2 promotes the
epithelial-mesenchymal transition process in pancreatic cancer cells[48]. Our data was incom-
patible with these theories, therefore it may be important to evaluate the relationship of tumor
microenvironment and IL13 signaling. Besides, IL13RA2 is associated with several types of
cancer progression, including the EMT of prostate cancer [26, 27]. Furthermore, IL13 initiates
an intracellular cascade that functions via 15-LOX-1 to activate PPAR-γ by phosphorylation of
STAT6 and regulate cell proliferation and apoptosis. Silencing of IL13RA2 also promotes glio-
blastoma cell death by inducing apoptosis [28]. Together this indicates that upregulation of
IL13RA2 inhibits apoptosis.
Generally, in 786-O tumor xenograft model, MVD in sensitive status was significantly
decreased by sunitinib treatment, but after long term of sunitinib treatment MVD in resistant
status was slightly increased in compared with sensitive status. This mechanism was suggested
that other angiogenic factors (e.x. IL-8, FGF-1/2, Ang1 etc.) were elevated or induced by anti-
angiogenic treatment [24].
In addition to these theories, our data suggested that IL13RA2 expression was correlated
with tumor growth and sensitivity to sunitinib. Sunitinib failed to suppress tumor growth of
786-O xenograft tumors when IL13RA2 was overexpressed, and sunitinib inhibited tumor
growth of Caki-1 xenograft tumors knocked down for IL13RA2 in vivo. Additionally, growth
Fig 5. Evaluation of apoptosis andmicrovessel density after sunitinib treatment in our primary xenograft models. (A) ssDNA staining and (B) CD31
staining of KURC1 treated with sunitinib or vehicle with different sensitivity status. Scale bar, 50 μm. Apoptosis was assessed by calculating the ssDNA
positivity rate, and MVD was determined from CD31 staining using Image J software. Statistical analysis was performed using the Students’ t-test
(*P < 0.01).
doi:10.1371/journal.pone.0130980.g005
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of xenograft tumors was promoted by upregulation of IL13RA2 and suppressed by silencing of
IL13RA2. And moreover, MVD was also decreased by sunitinib treatment independent of
IL13RA2 expression level. These data suggested that the mechanisms of acquired resistance
related with IL13RA2 expression were not associated with re-angiogenesis in tumors despite
the observations in previous reports [25, 49].
It was reported that tumor apoptosis was induced by upregulation of IL13RA2 in glioblas-
toma cells [28]. Another report showed that sunitinib induced apoptosis by inhibition of
STAT3 [50]. In our model, overexpression of IL13RA2 inhibited tumor apoptosis induced by
sunitinib and silencing of IL13RA2 promoted tumor apoptosis induced by sunitinib. These
data suggested that IL13RA2 expression was related to acquired resistance to sunitinib through
inhibiting tumor apoptosis, not via tumor re-angiogenesis. These findings were also seen in
our primary xenograft model.
Recent studies showed that targeting IL13RA2 may be a new therapy for glioblastoma and
head and neck squamous cell carcinoma [51, 52]. We conclude our observation suggests that
IL13RA2 could mediate resistance to sunitinib in certain population of ccRCC by avoiding
sunitinib-induced apoptosis. This is an unknown mechanism for acquiring resistance to suniti-
nib in addition to previous reports and suggests that IL13RA2 could be a potential target to
help overcome sunitinib resistance.
Supporting Information
S1 Fig. N-cadherin staining of KURC1 and KURC2 xenograft tumors. N-cadherin staining
of xenograft tumors derived from KURC1 and KURC2. Scale bar, 50 μm.
(PDF)
S2 Fig. Evaluation of FAM5B and MTMR7 mRNA expression. Evaluation of FAM5B and
MTMR7 mRNA expression in KURC1 and KURC2 xenograft tumors treated with sunitinib or
vehicle by qPCR. All samples were prepared in triplicate and data are presented as the
mean ± SE from indicated number of samples. Columns, mean; bar, SE. The difference in the
mRNA expression levels between the sunitinib-treated group and control or sensitive group in
KURC1 was statistically significant (P< 0.01; Students’ t-test). There was no significant dif-
ference in KURC2 groups.
(PDF)
S3 Fig. Evaluation of IL13RA2 mRNA and protein expression. (A) Evaluation of IL13RA2
mRNA expression in KURC1 xenograft tumors repeatedly treated with sunitinib or vehicle 5th
by qPCR. Columns, mean; bar, SE. The difference in the mRNA expression levels between the
sunitinib-treated group and vehicle group in KURC1 was statistically significant (P< 0.01;
Students’ t-test). (B) Immunohistochemical staining of IL13RA2 in KURC1 xenograft tumors
repeatedly treated with sunitinib 5th or vehicle 5th. Scale bar, 50 μm. (C) Immunohistochemical
staining of IL13RA2 in KURC2 xenograft tumors. Scale bar, 50 μm.
(PDF)
S4 Fig. Xenograft tumor growth of 786-O subclone. (A) IL13RA2 staining of xenograft
tumors derived from 786-O subclone overexpressing IL13RA2 or mock control. The difference
of IL13RA2 expression level was maintained in vivo. (B) Xenograft tumor growth of 786-O
subclone overexpressing IL13RA2 was increased compared with mock control. Day 0 is the
day of transplantation. The difference was statistically significant (P< 0.01; two-way repeated
ANOVA).
(PDF)
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S5 Fig. Xenograft tumor growth of Caki-1 subclone. (A) IL13RA2 staining of xenograft
tumors derived from Caki-1 subclone suppressed by shRNA-mediated knockdown of IL13RA2
and sh-scrambled subclones. The difference of IL13RA2 expression level was maintained in
vivo. (B) Xenograft tumor growth of Caki-1 subclone was suppressed by shRNA-mediated
knockdown of IL13RA2 (#525 and #526) compared with sh-scrambled subclones. Day 0 is the
day of transplantation. The difference was statistically significant (P< 0.01; two-way repeated
ANOVA).
(PDF)
S6 Fig. CD31 staining of cell line derived xenograft tumors. CD31 staining of xenograft
tumors derived from (A) 786-O subclones and (B) Caki-1 subclones treated with sunitinib or
control. Scale bar, 50 μm.
(PDF)
S7 Fig. ssDNA staining of cell line derived xenograft tumors. ssDNA staining of xenograft
tumors derived from (A) 786-O subclones and (B) Caki-1 subclones treated with sunitinib or
control. Scale bar, 50 μm.
(PDF)
S8 Fig. Gene expression data obtained from Oncomine. Data originated from Vasselli et al.
(21). Left: IL13RA2 mRNA expression of Grade 3 ccRCC versus Grade 4. Right: IL13RA2
mRNA expression of ccRCC patients alive at 1 year versus those dead at 1 year. Lower: Data
originated from Bittner IL13RA2 mRNA expression of ccRCC grouped by tumor grade.
(PDF)
S1 Table. mRNA changes after sunitinib treatment in KURC1 and KURC2 xenograft
tumors.Microarray analysis were performed using Affymetrix GeneChip Human Gene 1.0 ST
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